Biotechnology

IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE

SUZHOU, China, Oct. 21, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced IND application for a phase III clinical study of recombinant humanized anti-HER2 bispecific antibody KN026 (KN026-306) was official...

2021-10-21 10:31 2389

Singapore-based Biosyngen receives 500 million yuan in investment

SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- At the 12th Singapore-Guangdong Collaboration Council (SGCC) meeting held online onOctober 20, Singapore-based Biosyngen Pte. Ltd. ("Biosyngen") announced its partnership with wholly state-owned Chinese company Science City (Guangzhou) Investment Group Co....

2021-10-21 09:30 4708

GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research

PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...

2021-10-21 08:05 1797

EVERSANA and Intouch Group join forces, adding the premiere digital-first agency network to the market leader in next generation commercialization

CHICAGO and KANSAS CITY, Mo., Oct. 20, 2021 /PRNewswire/ -- EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, andIntouch Group®, a full-service global agency network serving the pharmaceutical industry, today announced that they signed an agreemen...

2021-10-20 22:34 3345

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen va...

2021-10-20 21:24 4331

Creatus Biosciences Inc. acquires the exclusive option to IP Assets from Stora Enso to Commercialize Xylitol Bioproduction from Biomass

VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- Creatus Biosciences Inc. ("Creatus") have signed a purchase agreement with Virdia, LLC ("Virdia"), a wholly-owned subsidiary of Stora Enso Oyj ("Stora Enso") to commercialize end-to-end production of xylitol by fermentation from biomass. The agreement ...

2021-10-20 21:00 1506

HistoIndex and Galecto to Collaborate on Galecto's Phase 2a MYLOX-1 Clinical Trial to Advance Myelofibrosis Assessment with AI-based Stain-free Digital Pathology

SINGAPORE, Oct. 20, 2021 /PRNewswire/ -- HistoIndex , a global leading artificial intelligence digital pathology (AI-DP) provider, has announced a collaboration with Galecto, Inc., a biotechnology company focused on the development of novel treatments for fibrosis an...

2021-10-20 18:00 1605

Bridge Biotherapeutics Announces Initiation of the Phase I Clinical Trial for BBT-401 in China

* China Phase I study of BBT-401 had its first subject dosed in Chengdu, China * The company seeks to accelerate its business development activities with Daewoong, their partner for the development and commercialization of BBT-401 in 22 Asian countries SEONGNAM, South Korea and CHENGDU, China, ...

2021-10-20 07:00 1422

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...

2021-10-20 05:08 1662

Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer

HONG KONG and NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Insilico Medicine, an end-to-end AI-powered drug discovery company, today announced the appointment of Dr.Michelle Chen to the company's position of Chief Business Officer.  In this role, Dr. Chen will oversee the company's corporate strategie...

2021-10-19 23:30 2966

Excelra Announces Addition of Sudip Nandy to its Board of Directors

HYDERABAD, India, Oct. 19, 2021 /PRNewswire/ -- Excelra, a leading Data and Analytics provider for Life Science organizations, announced the appointment of Sudip Nandy to the company's board of directors effective 1st October 2021. Mr. Nandy is an acclaimed business leader with over 30 years of e...

2021-10-19 21:00 6172

Moët Hennessy Breaks New Ground For Innovation: The Robert-Jean De Vogüé Research Center

ÉPERNAY, France, Oct. 19, 2021 /PRNewswire/ -- Moët Hennessy, world leader of high-quality wine and spirits, inaugurates its new Robert-Jean de Vogüé Research Center dedicated to advancing knowledge and evolving practices. Today, climate change and biodiversity loss for more environmentally frien...

2021-10-19 21:00 2410

PharmAbcine Announces Patent Grant in Australia for Its Anti-VISTA Antibody

DAEJEON, South Korea, Oct. 19, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the patent for PMC-309, one of the Company's first immuno-oncology assets, has been ...

2021-10-19 20:00 1357

Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase II Trial in Patients with Thyroid Eye Disease

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Oct. 19, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in phase II trial for the treatment ...

2021-10-19 17:52 1798

FDA Pre-Submission for Saliva-Based Glucose Test to Replace Invasive Finger-Prick

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- The iQ Group Global Ltd (NSX.IQG), on behalf of its subsidiary, Life Science Biosensor Diagnostics Pty Ltd (LSBD), is pleased to announce that one of its licensees, GBS Inc (Nasdaq: GBS); a life sciences company operating in theAsia Pacific region, under lice...

2021-10-19 15:01 1653

CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...

2021-10-19 09:00 1683

Australian businesses invited to advance the future of healthcare technologies in the Medtronic APAC Innovation Challenge

SYDNEY, Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in healthcare technology, invites Australian businesses to participate in the newly launchedMedtronic APAC Innovation Challenge (MAIC). Providing an opportunity for innovators in the region to pitch and advance the...

2021-10-19 06:51 3060

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...

2021-10-18 20:00 1568

Farmmi Healthcare Subsidiary Receives BRC and HACCP Certifications

LISHUI, China, Oct. 18, 2021 /PRNewswire/ -- Farmmi, Inc. ("Farmmi" or the "Company") (NASDAQ: FAMI) announced that one of its healthcare subsidiaries, Zhejiang Farmmi Biotechnology Co., Ltd., has been assessed and has been awarded the certificate for compliance with the requirements of  BRC Glob...

2021-10-18 20:00 1655

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Develop...

2021-10-18 11:05 1723
1 ... 214215216217218219220 ... 307

Week's Top Stories